AbbVie Inc. SG&A Expenses

SG&A Expenses of ABBV for past 10 years: annual, quarterly and twelve month trailing (TTM) including SG&A Expenses growth rates and interactive chart. Selling, general and administrative expense (SG&A) is reported on the income statement as the sum of all direct and indirect selling expenses and all general and administrative expenses (G&A) of a company. SG&A, also known as SGA, includes all the costs not directly tied to making a product or performing a service. That is, SG&A includes the costs to sell and deliver products and services and the costs to manage the company. It includes administrative

Highlights and Quick Summary

  • SG&A Expenses for the quarter ending December 30, 2019 was $1.95 Billion (a 17.74% increase compared to previous quarter)
  • Year-over-year quarterly SG&A Expenses increased by 16.13%
  • Annual SG&A Expenses for 2019 was $6.94 Billion (a -6.18% decrease from previous year)
  • Annual SG&A Expenses for 2018 was $7.4 Billion (a 17.54% increase from previous year)
  • Annual SG&A Expenses for 2017 was $6.3 Billion (a 7.04% increase from previous year)
  • Twelve month SG&A Expenses ending December 30, 2019 was $6.94 Billion (a 0.32% increase compared to previous quarter)
  • Twelve month trailing SG&A Expenses decreased by -4.75% year-over-year
Trailing SG&A Expenses for the last four month:
30 Dec '19 29 Sep '19 29 Jun '19 30 Mar '19
$6.94 Billion $6.92 Billion $7.18 Billion $7.29 Billion
Visit for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical SG&A Expenses of AbbVie Inc.

Most recent SG&A Expensesof ABBV including historical data for past 10 years.

Interactive Chart of SG&A Expenses of AbbVie Inc.

AbbVie Inc. SG&A Expenses for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2019 $1,951.0 $1,657.0 $1,654.0 $1,680.0 $6,942.0
2018 $1,929.0 $1,919.0 $1,760.0 $1,791.0 $7,399.0
2017 $1,956.0 $1,457.0 $1,509.0 $1,373.0 $6,295.0
2016 $1,679.0 $1,381.0 $1,466.0 $1,355.0 $5,881.0
2015 $1,737.0 $1,474.0 $1,703.0 $1,473.0 $6,387.0
2014 $3,341.0 $1,595.0 $1,448.0 $1,340.0 $7,724.0
2013 $1,448.0 $1,261.0 $1,406.0 $1,237.0 $5,352.0
2012 $1,411.0 $1,085.0 $1,246.0 $1,247.0 $4,989.0
2011 $4,716.09 $1,177.92 $5,894.0
2010 $3,820.0
2009 $3,348.57

Business Profile of AbbVie Inc.

Sector: Medical
Industry: Drugs
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. It offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behcet's diseases; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenstrom's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides KALETRA, an anti-human immunodeficiency virus (HIV)-1 medicine used with other anti-HIV-1 medications to maintain viral suppression in HIV-1 patients; NORVIR, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and SYNAGIS to prevent respiratory syncytial virus infection at-risk infants. In addition, it offers AndroGel, a testosterone replacement therapy; CREON, a pancreatic enzyme therapy; Synthroid to treat hypothyroidism; and Lupron to treat prostate cancer, endometriosis, and central precocious puberty, as well as anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product; and ORILISSA, a non-peptide molecule gonadotropin-releasing hormone antagonist. It has collaborations with Alector, Inc.; Janssen Biotech, Inc.; Galapagos; Bristol-Myers Squibb Company; Calico Life Sciences LLC; Cystic Fibrosis Foundation; Dragonfly Therapeutics, Inc.; and Pan-Canadian Pharmaceutical Alliance. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.